List view / Grid view
16 April 2015 | By Victoria White
The FAMHP has given authorisation for the commencement of the Phase I clinical trial of FR104, a drug for controlling the regulation of the immune system...
7 April 2015 | By Victoria White
Ablynx has announced the start of a Phase IIb study to evaluate the efficacy and safety of ALX-0061 as a treatment for rheumatoid arthritis...
1 April 2015 | By Victoria White
The US treatment market for Rheumatoid Arthritis is set to increase in value from $6.4 billion in 2013 to $9.3 billion by 2020, says GBI Research...
14 January 2015 | By GlobalData
The global Rheumatoid Arthritis (RA) treatment market value will witness steady growth, from $15.6 billion in 2013 to $19.3 billion in 2023, at a Compound Annual Growth Rate (CAGR) of 2.1%, according to research and consulting firm GlobalData...
10 November 2014 | By KU Leuven
A new drug combination for rheumatoid arthritis treats the disease just as well as other intensive treatment strategies but with less medication and fewer side effects at a significantly lower cost...
8 September 2014 | By Roche
Roche announced that RoACTEMRA (tocilizumab) has received approval from the European Commission for use in patients with severe, active and progressive RA who previously have not been treated with methotrexate...
25 September 2013 | By Pfizer
Long-term safety and efficacy data of XELJANZ up to five years will be presented at the American College Of Rheumatology 2013 annual meeting...
16 July 2013 | By Pfizer Inc.
Pfizer provides update on XELJANZ® (tofacitinib citrate) for the treatment of rheumatoid arthritis...
10 June 2013 | By Roche
“This approval comes earlier than expected, just one month following the positive CHMP opinion...”
27 July 2012 | By Roche
Data will be submitted to health authorities globally...
23 July 2012 | By Roche
Almost four times as many patients achieve remission with RoActemra (tocilizumab) compared to Humira (adalimumab)...
27 June 2012 | By Janssen Research & Development, LLC
Treatment also resulted in significant improvements in physical function...
